Filter articles using the following links

GenSight Biologics Reports Interim Financial Results for the First Half of 2017

Publication of the securities note having obtained visa no. 17-297 of the AMF in connection with the capital increase of GenSight Biologics

GenSight Biologics successfully raises €22.5 million from leading investors in the US and Europe

GenSight Biologics launches a capital increase of approximately €20 million

BIO International Convention, San Diego, CA (US)

GenSight Biologics reports long-term positive safety and visual acuity results at Week 96 in Phase I/II Study of GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

15ème Forum Santé Gilbert Dupont, Paris (France)

ISCAS 2017, Baltimore, Maryland (US)

GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO

2017 ARVO Annual Meeting, Baltimore, Maryland (US)